PTGX stock forecast
Our latest prediction for Protagonist Therapeutics, Inc.'s stock price was made on the Aug. 6, 2019 when the stock price was at 9.69$.
In the short term (2weeks), PTGX's stock price should outperform the market by 0.67%. During that period the price should oscillate between -8.36% and +12.95%.
In the medium term (3months), PTGX's stock price should outperform the market by 0.27%. During that period the price should oscillate between -19.29% and +33.36%.Get email alerts
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
At the moment the company generates 2M USD in revenues.
On its last earning announcement, the company reported a loss of -2.74$ per share.
The book value per share is 5.07$
Three months stock forecastAug. 6, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|